Temporal optimization of CD25-biased IL-2 agonists and immune checkpoint blockade leads to synergistic anticancer activity despite robust regulatory T cell expansion
Our findings support the temporally optimized use of CD25-biased IL-2-based therapeutics in combination with ICIs for cancer immunotherapy.
Authors
- İrfan Baki Kılıç (ORCID: https://orcid.org/0000-0002-1225-9920)
- Derek VanDyke (ORCID: https://orcid.org/0000-0002-0494-7184)
- Milada Šírová (ORCID: https://orcid.org/0000-0002-7645-1495)
- Vladyslav Mazhara
- Marek Kovář (ORCID: https://orcid.org/0000-0002-6602-1678)
- Kateřina Běhalová
- Jamie B. Spangler (ORCID: https://orcid.org/0000-0001-8187-3732)
- Blanka Řı́hová
- Petra Weberova
- Charina S. Fabilane
- Kathy Liu (ORCID: https://orcid.org/0000-0002-1531-3443)
- Bohumil Ptacek
- Katerina Kubesova
Institutions
- Bloomberg (United States) (US)
- Johns Hopkins University (US)
- Czech Academy of Sciences (CZ)
- Johns Hopkins Medicine (US)
- Institute of Microbiology (BY)
- Sidney Kimmel Cancer Center (US)
- Czech Academy of Sciences, Institute of Microbiology (CZ)
- Sidney Kimmel Comprehensive Cancer Center (US)
Publication Details
- Journal
- Journal for ImmunoTherapy of Cancer
- Published
- 2025-08-01
- DOI
- https://doi.org/10.1136/jitc-2024-010465
- Citations
- 1
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 1.05
Funders
- National Science Foundation
- U.S. Department of Defense
- Ministerstvo Školství, Mládeže a Tělovýchovy
- Grantová Agentura České Republiky
- National Institutes of Health